Ceftazidime in acute myeloid leukemia patients with febrile neutropenia: helpfulness of continuous intravenous infusion in maximizing pharmacodynamic exposure (Q33938048)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Ceftazidime in acute myeloid leukemia patients with febrile neutropenia: helpfulness of continuous intravenous infusion in maximizing pharmacodynamic exposure	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

30 July 2017

Ceftazidime in acute myeloid leukemia patients with febrile neutropenia: helpfulness of continuous intravenous infusion in maximizing pharmacodynamic exposure (English)

1 reference

Europe PubMed Central

30 July 2017

1 reference

based on heuristic

inferred from title

acute myeloid leukemia

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

pharmacodynamics

1 reference

based on heuristic

inferred from title

Pierluigi Viale

2

object named as

Pierluigi Viale

1 reference

Europe PubMed Central

30 July 2017

Francesco Cristini

5

object named as

Francesco Cristini

1 reference

Europe PubMed Central

30 July 2017

7

object named as

Mario Furlanut

1 reference

Europe PubMed Central

30 July 2017

4

object named as

Federica Pavan

1 reference

Europe PubMed Central

30 July 2017

author name string

Federico Pea

1

1 reference

Europe PubMed Central

30 July 2017

Daniela Damiani

3

1 reference

Europe PubMed Central

30 July 2017

Renato Fanin

6

1 reference

Europe PubMed Central

30 July 2017

language of work or name

0 references

publication date

1 August 2005

1 reference

Europe PubMed Central

30 July 2017

Antimicrobial Agents and Chemotherapy

1 reference

Europe PubMed Central

30 July 2017

49

1 reference

Europe PubMed Central

30 July 2017

8

1 reference

Europe PubMed Central

30 July 2017

3550-3553

1 reference

Europe PubMed Central

30 July 2017

Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1196227

5 July 2018

Is there a pharmacodynamic need for the use of continuous versus intermittent infusion with ceftazidime against Pseudomonas aeruginosa? An in vitro pharmacodynamic model

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1196227

5 July 2018

Teicoplanin in patients with acute leukaemia and febrile neutropenia: a special population benefiting from higher dosages

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1196227

5 July 2018

Treatment of febrile neutropenia: what is new?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1196227

5 July 2018

2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1196227

5 July 2018

Stability and compatibility of ceftazidime administered by continuous infusion to intensive care patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1196227

5 July 2018

Pharmacokinetics of ceftazidime in febrile neutropenic patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1196227

5 July 2018

Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1196227

5 July 2018

Is continuous infusion of beta-lactam antibiotics worthwhile?--efficacy and pharmacokinetic considerations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1196227

5 July 2018

Population pharmacokinetic study of teicoplanin in severely neutropenic patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1196227

5 July 2018

Continuous infusion of ceftazidime in febrile neutropenic patients with acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1196227

5 July 2018

Increased aminoglycoside dosage requirements in hematologic malignancy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1196227

5 July 2018

Prediction of creatinine clearance from serum creatinine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1196227

5 July 2018

Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1196227

5 July 2018

Bacteraemia in hospitalised patients with malignant blood disorders: a retrospective study of causative agents and their resistance profiles during a 14-year period without antibacterial prophylaxis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1196227

29 October 2018

Prospective evaluation of the epidemiology, microbiology, and outcome of bloodstream infections in hematologic patients in a single cancer center

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1196227

29 October 2018

Influence of malignancy on the pharmacokinetics of vancomycin in infants and children.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1196227

29 October 2018

Population pharmacokinetics of amikacin in patients with haematological malignancies

1 reference

https://pubmed.ncbi.nlm.nih.gov/16048982

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Vancomycin pharmacokinetics and dosage requirements in hematologic malignancies

1 reference

https://pubmed.ncbi.nlm.nih.gov/16048982

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetic parameters of vancomycin for therapeutic regimens in neutropenic adult patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/16048982

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Alternative method for determination of ceftazidime in plasma by high-performance liquid chromatography

1 reference

https://pubmed.ncbi.nlm.nih.gov/16048982

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1128/AAC.49.8.3550-3553.2005

1 reference

Europe PubMed Central

30 July 2017

1 reference

Europe PubMed Central

30 July 2017

1 reference

Europe PubMed Central

30 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33938048&oldid=2143924175"